BiotechTube
Anemocyte

Anemocyte

Milan, Italy· Est.
anemocyte.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

Anemocyte is a private, revenue-generating CDMO positioned in the high-growth cell and gene therapy (CGT) and mRNA manufacturing sector. The company provides essential plasmid and mRNA manufacturing services, supplemented by proprietary platforms like AMCAP™ for mRNA capping and AMClarity for visual inspection. With a strong emphasis on talent and sustainability, as evidenced by its Gender Equality Certification and published Sustainability Report, Anemocyte is scaling its operational and commercial presence, actively participating in major global industry conferences to engage partners and clients.

Cell TherapyRegenerative Medicine

Technology Platform

Specialized CDMO for plasmid DNA and mRNA manufacturing. Proprietary platforms include AMCAP™ for mRNA capping and AMClarity for automated visual inspection.

Funding History

1
Total raised:$15M
Series A$15M

Opportunities

High growth in cell/gene therapy and mRNA markets drives demand for plasmid and mRNA CDMO services.
Expansion into the US market via its Miami office provides access to the world's largest biopharma client base.
Proprietary platforms (AMCAP™, AMClarity) offer potential for higher-margin product sales and differentiation from competitors.

Risk Factors

Intense competition from larger, established CDMOs and other specialized manufacturers.
Operational risks associated with scaling GMP manufacturing and maintaining consistent quality for a global clientele.
Dependency on the clinical and commercial success of client therapeutic programs, which are inherently risky.

Competitive Landscape

Operates in a highly competitive CDMO sector competing against large multinationals (e.g., Lonza, Thermo Fisher, Catalent) and a growing number of niche players. Differentiation is sought through specialization in nucleic acids, proprietary technology platforms, and a strong focus on client service for small-mid size biotechs. Geographic presence in Europe with a US foothold is a strategic advantage.

More companies in mRNA Therapeutics →More companies in Italy →